AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22999671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate mouthwash
Number of subjects: 35
Study 22999671 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 35
Study 20354275 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-core prostate biopsy scheme
Number of subjects: 304
Study 20354275 — intervention group
Group type: COMPARATOR
Intervention: sextant biopsy scheme
Number of subjects: 304
Study 19192859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine contingency (four prize draws for each cocaine-negative urine)
Number of subjects: 67
Study 19192859 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate-cocaine contingency (one draw for each urine negative for opiates or cocaine, four draws if negative for both)
Number of subjects: 67
Study 19192859 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate-cocaine contingency
Number of subjects: 67
Study 19192859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine contingency
Number of subjects: 67
Study 15852492 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 30 mg/day
Number of subjects: 40
Study 15852492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14607390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (sertraline, phenelzine, or bupropion) for 8 weeks
Number of subjects: 28
Study 12884887 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus buprenorphine (12 mg/d)
Number of subjects: 180
Study 12884887 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d) plus methadone (65 mg/d)
Number of subjects: 180
Study 12884887 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d)
Number of subjects: 180
Study 12884887 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus buprenorphine (12 mg/d)
Number of subjects: 180
Study 12884887 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methadone (65 mg/d)
Number of subjects: 180
Study 8730616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium sp fermented milk with placebo
Number of subjects: 12
Study 8730616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium sp fermented milk with inulin (18g/d)
Number of subjects: 12
Study 8730616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study 1986877 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival probabilities displayed at bedside and staff viewed a videotape on measurement of survival probabilities and costs of pediatric intensive care.
Number of subjects: 436
Study 1986877 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients did not receive survival probabilities but healthcare workers viewed the videotape).
Number of subjects: 436
Study 6355500 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and grafting
Number of subjects: 47
Study 6355500 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with silver sulfadiazine cream
Number of subjects: 47
Study 31917447 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 61
Study 31917447 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 61
Study 31917447 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle weight loss intervention (LWLI)
Number of subjects: 61
Study 31917447 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 61
Study 31917447 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 61
Study 31917447 — intervention group
Group type: COMPARATOR
Intervention: LWLI
Number of subjects: 61
Study 31393319 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor‐Office Collaborative Care (DOCC)
Number of subjects: 8
Study 31393319 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 8
Study 30362939 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient bath additives plus standard eczema care
Number of subjects: 482
Study 30362939 — intervention group
Group type: COMPARATOR
Intervention: Standard eczema care alone (no bath additives)
Number of subjects: 482
Study 30362939 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 482
Study 27499517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg
Number of subjects: 220
Study 27499517 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 220
Study 25411291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 751
Study 25411291 — intervention group
Group type: COMPARATOR
Intervention: Non-breastfeeding
Number of subjects: 751
Study 23171800 — intervention group
Group type: EXPERIMENTAL
Intervention: NOYA biodegradable polymer sirolimus-eluting stent
Number of subjects: 300
Study 23171800 — intervention group
Group type: COMPARATOR
Intervention: FIREBIRD2 durable polymer sirolimus-eluting stent
Number of subjects: 300
Study 20210907 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FTG, two 1-hour sessions per week)
Number of subjects: 25
Study 20210907 — intervention group
Group type: COMPARATOR
Intervention: Control group (doctoral advice group, DAG)
Number of subjects: 25
Study 17935929 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention (enhanced intervention [EI])
Number of subjects: 923
Study 17935929 — intervention group
Group type: COMPARATOR
Intervention: Standard human immunodeficiency virus education (standard intervention [SI])
Number of subjects: 923
Study 17935929 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 923
Study 16006259 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily for 3 months)
Number of subjects: 93
Study 16006259 — intervention group
Group type: COMPARATOR
Intervention: No vitamin treatment (control group)
Number of subjects: 93
Study 12450955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 38
Study 12450955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10390316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nimodipine (30 mg every 6 hours)
Number of subjects: 50
Study 10390316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8683244 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) cisplatin 100 mg/m2
Number of subjects: 159
Study 8683244 — intervention group
Group type: COMPARATOR
Intervention: Low dose (LD) cisplatin 50 mg/m2
Number of subjects: 159
Study 1839703 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic plasma TFE
Number of subjects: 51
Study 1839703 — intervention group
Group type: COMPARATOR
Intervention: Gore-Tex polytetrafluoroethylene (PTFE)
Number of subjects: 51
Study 6666695 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help program delivered via a written manual and limited duration phone calls
Number of subjects: 0
Study 30344172 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia with tramadol
Number of subjects: 1230
Study 30344172 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with hydromorphone
Number of subjects: 1230
Study 30344172 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia with ropivacaine
Number of subjects: 1230
Study 27338717 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge coated with human coagulation factors (test group, n=44)
Number of subjects: 91
Study 27338717 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=47)
Number of subjects: 91
Study 25247318 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation (150 mg, increasing by 50 mg every 2 weeks, maximum 250 mg)
Number of subjects: 146
Study 25247318 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose erlotinib (100 mg per day)
Number of subjects: 146
Study 25247318 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation
Number of subjects: 146
Study 25247318 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose erlotinib
Number of subjects: 146
Study 23015113 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (n=45)
Number of subjects: 90
Study 23015113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90
Study 23015113 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel vs. Placebo (delta values)
Number of subjects: 90
Study 23015113 — intervention group
Group type: EXPERIMENTAL
Intervention: VerifyNow® response
Number of subjects: 90
Study 23015113 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus area in hypo-responders vs. good responders
Number of subjects: 90
Study 23015113 — intervention group
Group type: COMPARATOR
Intervention: Thrombus area in T2DM vs. non-diabetic patients
Number of subjects: 90
Study 20965851 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (facial mask ventilation)
Number of subjects: 56
Study 20965851 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation (mechanical ventilation by tracheal intubation or tracheal incision)
Number of subjects: 56
Study 20965851 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation
Number of subjects: 56
Study 17917555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 253
Study 17917555 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (10-30 mg/day)
Number of subjects: 253
Study 17917555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 253
Study 17917555 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 253
Study 16180181 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (150‐300 mg)
Number of subjects: 40
Study 16180181 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (150‐450 mg)
Number of subjects: 40
Study 16180181 — intervention group
Group type: COMPARATOR
Intervention: Both Propafenone and Amiodarone
Number of subjects: 40
Study 12187545 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine glutamate (6 g) plus yohimbine HCl (6 mg)
Number of subjects: 24
Study 12187545 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine alone (6 mg)
Number of subjects: 24
Study 12187545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 10442189 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT and concomitant bolus FU administration with additional chemotherapy (FU 600 mg/m2/week x 6 + LV 500 mg/m2/week x 6) followed by pelvic RT with FU (400 mg/m2) during RT
Number of subjects: 220
Study 10442189 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RT and concomitant FU only
Number of subjects: 220
Study 7617181 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1 (20 mg daily subcutaneous injection for 2 years)
Number of subjects: 251
Study 7617181 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1
Number of subjects: 251
Study 7617181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 2774639 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz rays administered once weekly for 4 weeks
Number of subjects: 14
Study 2774639 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 1273596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication (methylphenidate)
Number of subjects: 0
Study 1273596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30699155 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized-debunking training
Number of subjects: 0
Study 30699155 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual training
Number of subjects: 0
Study 25792303 — intervention group
Group type: EXPERIMENTAL
Intervention: Early individualised manipulative rehabilitation (twice a week for 4 weeks, 30 minutes per session)
Number of subjects: 21
Study 25792303 — intervention group
Group type: COMPARATOR
Intervention: Active control care
Number of subjects: 21
Study 25792303 — intervention group
Group type: EXPERIMENTAL
Intervention: Early individualised manipulative rehabilitation
Number of subjects: 21
Study 24682612 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural conception
Number of subjects: 251
Study 24682612 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 251
Study 24682612 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent pregnancy after RM diagnosis
Number of subjects: 251
Study 24682612 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous miscarriages
Number of subjects: 251
Study 24933974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with psychotropic medication plus valemidin
Number of subjects: 0
Study 24933974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard basic therapy plus valemidin
Number of subjects: 0
Study 24933974 — intervention group
Group type: COMPARATOR
Intervention: Standard basic therapy
Number of subjects: 0
Study 19464000 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with piezoelectric stimulation (Group IA)
Number of subjects: 71
Study 19464000 — intervention group
Group type: COMPARATOR
Intervention: Standard ICSI procedure (Group IB)
Number of subjects: 71
Study 19464000 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI with piezoelectric activation (Group II)
Number of subjects: 71
Study 17516115 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-Fr straight plastic stent
Number of subjects: 63
Study 17516115 — intervention group
Group type: COMPARATOR
Intervention: 10-Fr straight plastic stent
Number of subjects: 63
Study 17516115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 17170609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg
Number of subjects: 320
Study 17170609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg
Number of subjects: 320
Study 17170609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg
Number of subjects: 320
Study 17170609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 14578787 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial pedicle/vertical pattern reduction (group II)
Number of subjects: 208
Study 14578787 — intervention group
Group type: COMPARATOR
Intervention: Wise pattern reduction (group I)
Number of subjects: 208
Study 14578787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 208
Study 10766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (Celin 500 mg) and Vitamin E (Evion 400 mg) for 90 days along with tamoxifen (10 mg twice a day)
Number of subjects: 0
Study 10766415 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment alone
Number of subjects: 0
Study 9364758 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (writing deepest thoughts and feelings about the exam)
Number of subjects: 0
Study 9364758 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about a trivial topic)
Number of subjects: 0
Study 7828255 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium 30 micrograms.kg‐1
Number of subjects: 60
Study 7828255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 70 micrograms.kg‐1
Number of subjects: 60
Study 7828255 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg‐1 (with atropine)
Number of subjects: 60
Study 7828255 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 60
Study 3287972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (single 2 g preoperative dose)
Number of subjects: 289
Study 3287972 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 g perioperative doses)
Number of subjects: 289
Study 3287972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 289
Study 3287972 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 289
Study 3287972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan and Cefoxitin
Number of subjects: 289
Study 30239963 — intervention group
Group type: EXPERIMENTAL
Intervention: RAxML
Number of subjects: 3950
Study 30239963 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTRAL
Number of subjects: 3950
Study 30239963 — intervention group
Group type: EXPERIMENTAL
Intervention: NJst
Number of subjects: 3950
Study 30239963 — intervention group
Group type: EXPERIMENTAL
Intervention: SVDquartets
Number of subjects: 3950
Study 30239963 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtering by information content
Number of subjects: 3950
Study 27730670 — intervention group
Group type: EXPERIMENTAL
Intervention: European Guidelines publication
Number of subjects: 27942
Study 27730670 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional recommendations for apixaban
Number of subjects: 27942
Study 27730670 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional recommendations for dabigatran
Number of subjects: 27942
Study 27730670 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific recommendation for rivaroxaban
Number of subjects: 27942
Study 27730670 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trend
Number of subjects: 27942
Study 28285317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 100
Study 28285317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 24070456 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised pro-active fall prevention strategies from the clinical researcher
Number of subjects: 0
Study 24070456 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical grey matter volume
Number of subjects: 100
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumes of left lateral frontal orbital gyrus
Number of subjects: 100
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumes of right lateral frontal orbital gyrus
Number of subjects: 100
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 100
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral frontal orbital gyrus volume
Number of subjects: 100
Study 20826875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B (PIB) imaging
Number of subjects: 100
Study 19220913 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management with telemonitoring
Number of subjects: 478
Study 19220913 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 478
Study 17270055 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fasting conditions
Number of subjects: 30
Study 17270055 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fed conditions
Number of subjects: 30
Study 17270055 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fasting conditions with naltrexone 50-mg block
Number of subjects: 30
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 3 ng ml(‐1) until incision
Number of subjects: 61
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 5 ng ml(‐1) for intubation
Number of subjects: 61
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 10 ng ml(‐1) during intra-abdominal surgery
Number of subjects: 61
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 5-7 ng ml(‐1) during closure
Number of subjects: 61
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: High remifentanil concentration
Number of subjects: 61
Study 14982571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil concentrations
Number of subjects: 61
Study 11681648 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA delivered via pMDI with Azmacort spacer (75 microg)
Number of subjects: 10
Study 11681648 — intervention group
Group type: COMPARATOR
Intervention: TAA delivered via pMDI without spacer (230 microg)
Number of subjects: 10
Study 8652714 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimplantation technique
Number of subjects: 50
Study 8652714 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin regimen
Number of subjects: 50
Study 8652714 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 50
Study 8652714 — intervention group
Group type: EXPERIMENTAL
Intervention: Humoral and cell mediated immune responses
Number of subjects: 50
Study 1385913 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for the first 5 postoperative days (group A)
Number of subjects: 60
Study 1385913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin perioperatively and on the second and fourth postoperative days (group B)
Number of subjects: 60
Study 1385913 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group C)
Number of subjects: 60
Study 6429359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of starvation
Number of subjects: 14
Study 6429359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of refeeding with carbohydrate (n=6)
Number of subjects: 14
Study 6429359 — intervention group
Group type: COMPARATOR
Intervention: 5 days of refeeding without carbohydrate (n=6)
Number of subjects: 14
Study 6429359 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation
Number of subjects: 14
Study 6429359 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition in cachectic patients
Number of subjects: 14
Study 30773555 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactide (PLA) scaffolds
Number of subjects: 20
Study 30773555 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycaprolactone (PCL) scaffolds
Number of subjects: 20
Study 29316895 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive sensory stimulation (RSS)
Number of subjects: 71